Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma, Follicular 6Sarcoma 3Rhabdoid Tumor 2Lymphoma, Non-Hodgkin 2Lymphoma, B-Cell 2Xanthogranuloma, Juvenile 1Wilms Tumor 1Urinary Bladder Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Prostatic Neoplasms 1Ovarian Neoplasms 1Osteosarcoma 1Neurofibrosarcoma 1Neuroectodermal Tumors, Primitive, Peripheral 1Neuroblastoma 1Nerve Sheath Neoplasms 1Melanoma 1Medulloblastoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma 1Inhibition, Psychological 1Histiocytosis, Langerhans-Cell 1Histiocytic Sarcoma 1Hepatoblastoma 1Glioma 1Ependymoma 1Chordoma 1

Interventions

pembrolizumab 3romidepsin 2Specimen Handling 2Melphalan 2Gemcitabine 2Etoposide 2Cyclophosphamide 2Biopsy 210-propargyl-10-deazaaminopterin 2tazemetostat 1talimogene laherparepvec 1prednylidene 1fludarabine 1etoposide phosphate 1durvalumab 1deltacortene 1cc-486 1carmustine, poliferprosan 20 drug combination 1belinostat 1Whole-Body Irradiation 1Triamcinolone 1Tacrolimus 1Prednisone 1Pharmacokinetics 1Pharmacogenomic Variants 1Peripheral Blood Stem Cell Transplantation 1Oxaliplatin 1Nivolumab 1Mycophenolic Acid 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Lymphoma, T-Cell × tazemetostat × Clear all
NCT05627245 2026-05-13

Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment

National Cancer Institute (NCI)

Phase 1 Active not recruiting
48 enrolled
DermatologicLymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡